PT3757126T - Métodos de tratamento da artrite psoriática utilizando antagonistas da il-17 - Google Patents

Métodos de tratamento da artrite psoriática utilizando antagonistas da il-17

Info

Publication number
PT3757126T
PT3757126T PT201870011T PT20187001T PT3757126T PT 3757126 T PT3757126 T PT 3757126T PT 201870011 T PT201870011 T PT 201870011T PT 20187001 T PT20187001 T PT 20187001T PT 3757126 T PT3757126 T PT 3757126T
Authority
PT
Portugal
Prior art keywords
antagonists
methods
psoriatic arthritis
treating psoriatic
treating
Prior art date
Application number
PT201870011T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3757126(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3757126T publication Critical patent/PT3757126T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
PT201870011T 2010-11-05 2011-11-04 Métodos de tratamento da artrite psoriática utilizando antagonistas da il-17 PT3757126T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41053310P 2010-11-05 2010-11-05

Publications (1)

Publication Number Publication Date
PT3757126T true PT3757126T (pt) 2025-11-13

Family

ID=44906168

Family Applications (2)

Application Number Title Priority Date Filing Date
PT16163440T PT3111954T (pt) 2010-11-05 2011-11-04 Métodos de tratamento da espondilite anquilosante usando anticorpos anti-il-17
PT201870011T PT3757126T (pt) 2010-11-05 2011-11-04 Métodos de tratamento da artrite psoriática utilizando antagonistas da il-17

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT16163440T PT3111954T (pt) 2010-11-05 2011-11-04 Métodos de tratamento da espondilite anquilosante usando anticorpos anti-il-17

Country Status (30)

Country Link
US (10) US9744234B2 (OSRAM)
EP (6) EP3912640B1 (OSRAM)
JP (8) JP2014503482A (OSRAM)
KR (5) KR20180129991A (OSRAM)
CN (2) CN103189074A (OSRAM)
AU (1) AU2011325134B2 (OSRAM)
BR (1) BR112013011176A2 (OSRAM)
CA (2) CA3116725C (OSRAM)
CL (1) CL2013001213A1 (OSRAM)
CY (1) CY1121802T1 (OSRAM)
DE (1) DE20187001T1 (OSRAM)
DK (2) DK3111954T3 (OSRAM)
ES (3) ES2733712T3 (OSRAM)
FI (1) FI3757126T3 (OSRAM)
HR (2) HRP20251174T1 (OSRAM)
HU (1) HUE044038T2 (OSRAM)
IL (4) IL311014A (OSRAM)
LT (2) LT3757126T (OSRAM)
MA (1) MA34647B1 (OSRAM)
MX (1) MX362591B (OSRAM)
PH (1) PH12013500890A1 (OSRAM)
PL (1) PL3111954T3 (OSRAM)
PT (2) PT3111954T (OSRAM)
RS (1) RS67377B1 (OSRAM)
RU (1) RU2582937C2 (OSRAM)
SG (2) SG10201505624VA (OSRAM)
SI (1) SI3111954T1 (OSRAM)
TR (1) TR201909531T4 (OSRAM)
TW (3) TWI616204B (OSRAM)
WO (1) WO2012059598A2 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
KR20180129991A (ko) 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
SG10201707813YA (en) 2011-10-11 2017-11-29 Medimmune Llc Cd40l-specific tn3-derived scaffolds and methods of use thereof
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
CN105899231A (zh) 2013-10-22 2016-08-24 诺夫免疫股份有限公司 用于在具有升高水平的tlr4配体和其它生物标记的患者中诊断和治疗病症的方法和组合物
CN105916883B (zh) * 2014-01-28 2019-12-03 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
BR122023025321A2 (pt) 2014-05-13 2024-02-20 Medimmune Limited Uso de anticorpos anti-b7-h1 e anti-ctla-4
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2015176031A2 (en) 2014-05-15 2015-11-19 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
FR3021976B1 (fr) * 2014-06-06 2018-11-02 Hospices Civils De Lyon Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu
US20160002326A1 (en) * 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
NL2013007B1 (en) * 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
SI3191120T1 (sl) * 2014-09-10 2024-10-30 Novartis Ag Uporaba antagonistov IL-17 za zaviranje napredovanja strukturne poškodbe pri pacientih s psoriatičnim artritisom
CA2963995A1 (en) * 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AU2016226415B2 (en) 2015-03-02 2021-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a TNF receptor 2 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
IL297775A (en) * 2015-10-19 2022-12-01 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
JP2019534240A (ja) * 2016-08-23 2019-11-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
RU2020117362A (ru) * 2017-11-02 2021-12-02 Новартис Аг Способы лечения тендинопатии с помощью антагонистов интерлейкина-17 (il-17)
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CN112584857A (zh) * 2018-05-09 2021-03-30 诺华股份有限公司 卡那吉努单抗的用途
KR20210110287A (ko) * 2018-09-26 2021-09-07 비엘라 바이오, 인크. Cd40l 길항제 및 이의 용도
CA3125236A1 (en) * 2019-01-22 2020-07-30 F. Hoffmann-La Roche Ag Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
JP7266108B2 (ja) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
CA3150041A1 (en) * 2019-08-05 2021-02-11 Evelo Biosciences, Inc. Compositions and methods of treating psoriasis and atopic dermatitis using prevotella histicola
CN114981302A (zh) * 2019-09-20 2022-08-30 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗自身免疫性疾病的方法
CA3161801A1 (en) 2019-11-19 2021-05-27 Novartis Ag Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
WO2021146850A1 (en) * 2020-01-20 2021-07-29 Tsinghua University A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4
WO2022113105A1 (en) * 2020-11-25 2022-06-02 Dr. Reddy's Laboratories Limited Stable therapeutic protein formulation and methods of making the same
TW202241505A (zh) * 2021-01-04 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
KR102339377B1 (ko) * 2021-03-29 2021-12-13 김지혜 사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치
WO2022271544A1 (en) * 2021-06-21 2022-12-29 Bristol-Myers Squibb Company Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products
CN114306594A (zh) * 2021-12-21 2022-04-12 华中科技大学同济医学院附属协和医院 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用
EP4654999A1 (en) 2023-01-27 2025-12-03 Fresenius Kabi Deutschland GmbH Biopharmaceutical composition
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2025071335A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-17 항체의 안정한 액상 제형

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5250442A (en) * 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
NZ512122A (en) 1998-11-27 2003-12-19 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
JP4159682B2 (ja) 1998-12-22 2008-10-01 株式会社クラレ 止血材
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
WO2003041637A2 (en) 2001-11-09 2003-05-22 Centocor, Inc. Lyophilized monoclonal antibody compositions
US7332276B2 (en) 2002-03-01 2008-02-19 Celltech R&D, Inc. Methods to increase or decrease bone density
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US6974701B2 (en) 2003-03-21 2005-12-13 Hemovations, Llc Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8039642B2 (en) 2003-12-09 2011-10-18 Life Technologies Corporation Pyrenyloxysulfonic acid fluorescent agents
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP3936365B2 (ja) 2004-09-14 2007-06-27 ソニーケミカル＆インフォメーションデバイス株式会社 機能素子実装モジュール及びその製造方法
NZ560844A (en) 2005-03-08 2008-08-29 Pharmacia & Upjohn Co Llc Anti-MAdCAM antibody compositions
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US20090221568A1 (en) 2005-11-04 2009-09-03 Jared Shaw Synthesis of Inhibitors of FtsZ
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
AU2007235199B8 (en) 2006-01-31 2010-10-28 Novartis Ag IL-17 antagonistic antibodies for treating cancer
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
BRPI0714893A2 (pt) 2006-09-05 2013-05-28 Medarex Inc anticorpo monoclonal isolado ou uma porÇço de ligaÇço ao seu antÍgeno, um fragmento de anticorpo, um anticorpo mimÉtico, imunoconjugado, composiÇço molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-bmp2 ou anti-bmp4, mÉtodo para tratar ou prevenir uma doenÇa associada com formaÇço àssea normal e ossificaÇço, hibridoma e metodo para preparar o anticorpo
JPWO2008029908A1 (ja) 2006-09-07 2010-01-21 協和発酵キリン株式会社 抗体を含有する安定な凍結乾燥医薬製剤
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CN101541833B (zh) * 2006-10-02 2014-01-29 麒麟-安姆根有限公司 Il-17受体a抗原结合蛋白质
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2460828A3 (en) 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
US20100028335A1 (en) 2007-02-02 2010-02-04 Novartis Ag Compositions and Methods to Treat Bone Related Disorders
UA96474C2 (en) 2007-03-20 2011-11-10 Эли Лилли Энд Компани Anti-sclerostin antibodies
UA96473C2 (ru) 2007-03-22 2011-11-10 Имклоун Ллк Жидкая стойкая композиция, которая содержит антитело imc-а12
US20110130544A1 (en) * 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
AU2008266745B2 (en) * 2007-06-20 2014-04-17 Merck Sharp & Dohme Corp. Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
US7720605B2 (en) 2007-06-22 2010-05-18 Weyerhaeuser Nr Company Identifying vegetation attributes from LiDAR data
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EP2628486A3 (en) 2007-12-14 2013-10-30 Amgen, Inc. Method for treating bone fracture with anti-sclerostin antibodies
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20090301682A1 (en) 2008-06-05 2009-12-10 Baker Hughes Incorporated Casting furnace method and apparatus
KR20110031369A (ko) 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
BRPI0919531A2 (pt) 2008-09-29 2015-12-08 Roche Glycart Ag anticorpos contra il17 humana e usos dos mesmos
CN102438652B (zh) 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
FR2938547B1 (fr) 2008-11-14 2012-11-16 Total Raffinage Marketing Liant synthetique clair
US20110256130A1 (en) 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders
EP2810652A3 (en) 2009-03-05 2015-03-11 AbbVie Inc. IL-17 binding proteins
WO2012045848A1 (en) 2010-10-08 2012-04-12 Novartis Ag Methods of treating psoriasis using il-17 antagonists
KR20180129991A (ko) 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
AR084234A1 (es) * 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
KR20140097178A (ko) 2011-11-21 2014-08-06 노파르티스 아게 IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법
KR20150010709A (ko) 2012-04-20 2015-01-28 노파르티스 아게 Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
IL297775A (en) 2015-10-19 2022-12-01 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
US11280479B2 (en) 2017-10-18 2022-03-22 The Sloan Company Sign box light module

Also Published As

Publication number Publication date
RU2013125775A (ru) 2014-12-10
US20200276305A1 (en) 2020-09-03
SG10201505624VA (en) 2015-09-29
US20130209480A1 (en) 2013-08-15
TWI616204B (zh) 2018-03-01
IL225309A0 (en) 2013-06-27
EP3757126B1 (en) 2025-09-03
CN103189074A (zh) 2013-07-03
PT3111954T (pt) 2019-07-10
DK3757126T3 (da) 2025-09-29
JP2025102772A (ja) 2025-07-08
WO2012059598A2 (en) 2012-05-10
CA3116725A1 (en) 2012-05-10
LT3111954T (lt) 2019-07-10
US20230346926A1 (en) 2023-11-02
IL311014A (en) 2024-04-01
IL262559A (en) 2018-12-31
ES3030036T3 (en) 2025-06-26
JP6515168B2 (ja) 2019-05-15
EP3111954B1 (en) 2019-04-03
HRP20191162T1 (hr) 2019-10-04
KR20160067984A (ko) 2016-06-14
US20180008706A1 (en) 2018-01-11
KR20180129991A (ko) 2018-12-05
BR112013011176A2 (pt) 2020-09-01
CA2813849A1 (en) 2012-05-10
JP2019142912A (ja) 2019-08-29
IL282625A (en) 2021-06-30
EP3912640B1 (en) 2025-03-05
US20210128726A1 (en) 2021-05-06
IL225309B (en) 2021-05-31
SI3111954T1 (sl) 2019-08-30
EP3757126A1 (en) 2020-12-30
CL2013001213A1 (es) 2014-03-28
EP4116325A1 (en) 2023-01-11
WO2012059598A3 (en) 2012-09-27
JP2016065094A (ja) 2016-04-28
ES2804624T1 (es) 2021-02-08
FI3757126T3 (fi) 2025-10-12
EP3111954A1 (en) 2017-01-04
DK3111954T3 (da) 2019-07-15
AU2011325134A1 (en) 2013-04-04
US12465635B2 (en) 2025-11-11
RS67377B1 (sr) 2025-11-28
CY1121802T1 (el) 2020-07-31
JP2021104995A (ja) 2021-07-26
EP3912640A1 (en) 2021-11-24
US9744234B2 (en) 2017-08-29
IL262559B (en) 2022-06-01
US10363307B2 (en) 2019-07-30
TWI618543B (zh) 2018-03-21
US20230293683A1 (en) 2023-09-21
JP2023109910A (ja) 2023-08-08
JP6049843B2 (ja) 2016-12-21
AU2011325134B2 (en) 2014-10-23
MX2013005060A (es) 2013-06-28
LT3757126T (lt) 2025-12-10
US20250205332A1 (en) 2025-06-26
RU2582937C2 (ru) 2016-04-27
KR20140008305A (ko) 2014-01-21
MA34647B1 (fr) 2013-11-02
PL3111954T3 (pl) 2019-10-31
US20190307880A1 (en) 2019-10-10
TW201517917A (zh) 2015-05-16
US20220193234A1 (en) 2022-06-23
TR201909531T4 (tr) 2019-07-22
JP2014503482A (ja) 2014-02-13
JP2017002064A (ja) 2017-01-05
US11534491B2 (en) 2022-12-27
JP6250109B2 (ja) 2017-12-20
DE20187001T1 (de) 2021-04-01
HRP20251174T1 (hr) 2025-11-21
ES2733712T3 (es) 2019-12-02
CA2813849C (en) 2021-06-15
HUE044038T2 (hu) 2019-09-30
SG189138A1 (en) 2013-05-31
CN104800844A (zh) 2015-07-29
TW201726170A (zh) 2017-08-01
US20210177966A1 (en) 2021-06-17
PH12013500890A1 (en) 2013-07-01
KR20180019247A (ko) 2018-02-23
EP2635303A2 (en) 2013-09-11
MX362591B (es) 2019-01-25
CA3116725C (en) 2023-10-24
TW201306864A (zh) 2013-02-16
KR20150020734A (ko) 2015-02-26
TWI604851B (zh) 2017-11-11
EP3542820A1 (en) 2019-09-25
JP2018065826A (ja) 2018-04-26

Similar Documents

Publication Publication Date Title
IL282625A (en) Use of the il-17 antibody to prepare a drug for the treatment of ankylosing spondylitis and rheumatoid arthritis
IL225310A0 (en) Methods for treating psoriasis using 17-il antagonists
IL232001A0 (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
GB201014633D0 (en) Rheumatoid arthritis treatment
IL226401A0 (en) Methods for treating disorders related to @fgfBA
ZA201500152B (en) Methods of treating arthritis
ZA201207125B (en) Treatment of lupus arthritis using laquinimod
EP2628153A4 (en) METHOD FOR ESTABLISHING LINGUISTIC PROFILE
SG11201401287SA (en) Methods of treating liver conditions using notch2 antagonists
IL237554A0 (en) Treatment for rheumatoid arthritis
PT2621619E (pt) Processo de mistura
IL223290A0 (en) Arthritis treatment
IL286709A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
IL222948A0 (en) Novel methods for the prepartion of p2x7r antagonists
HK1185545A (en) Methods of treating rheumatoid arthritis using il-17 antagonists
GB201019641D0 (en) The process of delivering o-vouchers
ZA201501559B (en) Treatment for rheumatoid arthritis